India's leading science-based Ayurveda major Dabur India Ltd announced its financial results for the quarter ended June 30 2026, delivering resilient and broad-based growth in a challenging operating environment. The company reported 15% surge in net profit at Rs. 591 crore in Q1 of 2026-27, backed by 10.6% jump in consolidated revenue at Rs. 3,761 crore. India FMCG business reported 9.5% growth with an underlying volume growth of 5%.
Commenting on the results, Dabur India Ltd global chief executive officer Mohit Malhotra said: "This marks the third straight quarter of double-digit profit growth for Dabur. The quarter unfolded against a backdrop of persistent inflationary pressures, heightened geopolitical uncertainties in the MENA region, and volatile commodity markets. In this hyper-inflationary environment, our disciplined cost management with Project Samriddhi, operational efficiencies and judicious price increases helped report healthy profit growth during the quarter. Dabur ended the first quarter of 2026-27 with an 11% growth in operating profit. Net profit surged 15% to Rs. 591 crore.”
Dabur reported strong growth across its key verticals with market share gains across over 90% of the portfolio during the quarter. “Our multi-pronged strategy enabled us to grow margins while continuing to invest in future growth opportunities. Our performance demonstrates that even in uncertain times, consistent execution and consumer-centric innovation remain our strongest growth drivers,” Malhotra said.
“As per syndicated data, rural demand grew 170 basis points ahead of urban demand in the first quarter, with growth of 6.2% in rural versus 4.6% in urban markets. We believe this reflects a healthy broadening of India's consumption story across urban and rural India. While the consumption landscape is becoming more balanced, rural demand needs to watched especially in view of El-Nino, patchy monsoons and rising inflationary pressures,” Malhotra added.
“Recent launches such as Siens and Cheers have strengthened our presence in fast-evolving consumer segments and demonstrated our ability to identify and address emerging consumer needs. Going forward, we see premiumisation playing an increasingly important role in shaping the next phase of Dabur's growth story, while driving both market expansion and margin enhancement,” Malhotra said.
The quarter underscored the strength of Dabur's diversified portfolio, with each of our three business verticals – home & personal care (HPC), healthcare and food & beverages (F&B) – contributing meaningfully to growth.
While the HPC business posted a strong 12.3 growth, the F&B business grew by 7.2% and the Healthcare vertical reported a 5.5% growth. “The broad-based nature of this performance reflects the enduring consumer preference for our brands, the effectiveness of our innovation pipeline and the agility of our execution. Together, these businesses continue to create a diversified and resilient growth engine for Dabur,” he said.
In healthcare, digestives portfolio grew by 11.2% with all three brands – Hajmola tablets, Isabgol and PudinHara growing at strong double digits. Within the OTC business, brand Honitus grew by 28% and Health juices by 24%. In the health supplements business, our flagship brand Dabur Honey reported an 8% growth.
The foods category ended Q1 up 29.2% and the Badshah business grew by 13.2%. Despite a challenging start to the season due to rain-led demand disruptions, our Beverages business recovered strongly over the remainder of the quarter and returned to the positive territory with mid-single-digit growth in Q1. Our premium beverage portfolio continues to gain scale, with Real Activ Juices growing 42% and Coconut Water growing 73% during Q1. The strong traction in these categories reinforces our confidence in the long-term opportunity within health and wellness-led beverage segments.